Megan McArdle points out that the thought that one can have innovative pharmaceutical companies delivering new drugs at low cost under government direction is a fantasy. You can have lower costs, perhaps—though the military procurement process is hardly encouraging—but you cripple innovation, slowing progress against disease.
